Understanding EGF receptor activation by growth factors and oncogenic mutations

了解生长因子和致癌突变对 EGF 受体的激活

• 批准号: 10393025
• 负责人: KATHRYN M FERGUSON
• 金额: $ 52.07万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-18 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10393025
• 关键词: AREG gene; Affect; Affinity; Agonist; Antibodies; Behavior; Binding; Biochemical; Biophysics; Cancer Etiology; Cells; Clinic; Clinical; Coupled; Crystallization; Data; Databases; Deuterium; Dimerization; Disease; EGF gene; ERBB3 gene; Enzymatic Biochemistry; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Epiregulin; Exons; Extracellular Domain; Family member; Fc Receptor; Funding; G-Protein-Coupled Receptors; Gene Amplification; Generations; Glioblastoma; Goals; Growth Factor; Hydrogen; Kinetics; Ligands; Malignant Neoplasms; Malignant neoplasm of lung; Mass Spectrum Analysis; Measures; Microprocessor; Molecular Conformation; Mutate; Mutation; Nature; Oncogenic; Outcome; Patients; Pharmaceutical Preparations; Phosphotransferases; Property; Receptor Activation; Receptor Protein-Tyrosine Kinases; Receptor Signaling; Reporting; Resistance; Resolution; Signal Transduction; Specificity; Structure; Testing; Therapeutic Intervention; Transmembrane Domain; Tyrosine Kinase Domain; Tyrosine Kinase Inhibitor; Variant; Work; base; cancer cell; dimer; epigen; extracellular; inhibitor; inhibitor therapy; insight; kinase inhibitor; mutant; novel therapeutic intervention; receptor; response; success; targeted treatment

The epidermal growth factor receptor (EGFR) is often described as a ‘prototypic’ receptor tyrosine kinase (RTK). As one of the first single transmembrane domain receptors for which ligand-induced dimerization was reported, the ‘traditional’ view of EGFR (and other RTKs) has been of a binary ‘off’/‘on’ switch. Our previous work, together with recent work on similar receptors, instead argues that signaling by receptors of this type is much more ‘graded’ – and that EGFR and other receptors can discriminate between different ligands. Indeed, we showed that different EGFR-activating ligands can induce receptor dimers with distinct structures – leading to different signaling kinetics and orthogonal cellular outcomes. Remarkably, the key residues that define the differences between the structures of these dimers coincide with the hotspots for extracellular EGFR mutations in glioblastoma. We therefore hypothesize here that EGFR mutations in GBM may exert at least part of their effect by altering the nature of the signaling response to different EGFR ligands. This would open the possibility of ‘correcting’ EGFR signaling in cancer if antibodies or other agents could be developed to reprogram them as ‘allosteric microprocessors’ by analogy with biased agonists for G-protein coupled receptors. Primary resistance to EGFR inhibitors in glioblastoma and in lung cancer is an important clinical problem that limits success with existing EGFR-targeted tyrosine kinase inhibitors (TKIs). Static structural views of kinase domains have not allowed satisfying explanations for the relative abilities of TKIs to inhibit different variants – leaving the origins of primary resistance and of mutant selectivity (e.g. of osimertinib) unclear and difficult to solve. New instances of acquired TKI resistance suffer from the same problem. Our studies using hydrogen-deuterium exchange mass spectrometry (HDX-MS) alongside enzymology suggest that the key may lie in the effects of both the mutations and the TKIs themselves on structural dynamics – particularly in the case of 3rd generation covalent EGFR inhibitors that associate with their targets in multiple steps. With this background, the key overall goal of this proposal is to identify specific behavior of EGFR variants seen in cancer that can explain their altered signaling properties and altered sensitivity to inhibitors. We apply a range of biophysical, structural, biochemical, and cellular approaches to interrogate signaling at several levels of resolution. In addition to answering key mechanistic questions for EGFR, our results should illuminate potential new avenues for therapeutic intervention. Our Specific Aims ask the following questions: 1 How do disease-associated extracellular mutations in EGFR family members affect signaling specificity and kinetics? 2 Can structural dynamics explain primary kinase inhibitor resistance of exon 19 EGFR variants in lung cancer, and selectivity of 3rd generation covalent inhibitors?

表皮生长因子受体（EGFR）通常被描述为一种“原型”受体酪氨酸激酶 （RTK）。作为第一个单跨膜结构域受体之一，其配体诱导的二聚化是 据报道，EGFR（和其他RTK）的“传统”观点是二元“关”/“开”开关。我们以前的 的工作，以及最近对类似受体的工作，相反，认为这种类型的受体的信号是 EGFR和其他受体可以区分不同的配体。的确， 我们发现不同的EGFR激活配体可以诱导具有不同结构的受体二聚体， 不同的信号动力学和正交细胞结果。值得注意的是，定义蛋白质的关键残基 这些二聚体结构之间的差异与细胞外EGFR突变的热点一致 胶质母细胞瘤因此，我们在此假设GBM中的EGFR突变可能至少部分地发挥其作用。 通过改变对不同EGFR配体的信号应答的性质来影响。这将打开 如果可以开发抗体或其他药物， 通过与G蛋白偶联的偏向性激动剂类比，将它们重新编程为“变构微处理器”。 受体。 胶质母细胞瘤和肺癌对EGFR抑制剂的原发性耐药是一个重要的临床问题 这限制了现有EGFR靶向酪氨酸激酶抑制剂（TKI）的成功。静态结构视图 激酶结构域还不能令人满意地解释TKI抑制不同细胞因子的相对能力。 变异体-原发性耐药和突变体选择性（例如奥希替尼）的起源不清楚， 很难解决。获得性TKI耐药性的新实例遭受同样的问题。我们的研究使用 氢氘交换质谱（HDX-MS）和酶学研究表明， 在于突变和TKI本身对结构动力学的影响-特别是在 第三代共价EGFR抑制剂的情况下，与他们的目标，在多个步骤。 在此背景下，该提案的关键总体目标是确定EGFR变体的特定行为 这可以解释它们改变的信号特性和对抑制剂的敏感性。我们应用 一系列的生物物理，结构，生物化学和细胞方法来询问信号在几个 分辨率的水平。除了回答EGFR的关键机制问题外，我们的结果还应阐明 治疗干预的潜在新途径。我们的具体目标提出以下问题： 1 EGFR家族成员的疾病相关细胞外突变如何影响信号传导特异性 动力学？ 2结构动力学能否解释EGFR 19号外显子变异体在肺组织中的原发性激酶抑制剂耐药 癌症和第三代共价抑制剂的选择性？